The positive feedback from Key Opinion Leaders during pre-clinical animal studies indicates a high level of satisfaction with the LIBERTY Robotic Surgical System. This, combined with the acceptance of two peer-reviewed abstracts for presentation at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), suggests that the system is well-regarded by experts in the field. As a result, this news is likely to have a positive short-term impact on Microbot Medical's stock price, as it may accelerate adoption of the system once it is commercialized.